Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Energy metabolism in glioblastoma stem cells: PPARα a metabolic adaptor to intratumoral microenvironment.

Fidoamore A, Cristiano L, Laezza C, Galzio R, Benedetti E, Cinque B, Antonosante A, d'Angelo M, Castelli V, Cifone MG, Ippoliti R, Giordano A, Cimini A.

Oncotarget. 2017 Jul 7;8(65):108430-108450. doi: 10.18632/oncotarget.19086. eCollection 2017 Dec 12.

2.

Deregulated expression and activity of Farnesyl Diphosphate Synthase (FDPS) in Glioblastoma.

Abate M, Laezza C, Pisanti S, Torelli G, Seneca V, Catapano G, Montella F, Ranieri R, Notarnicola M, Gazzerro P, Bifulco M, Ciaglia E.

Sci Rep. 2017 Oct 26;7(1):14123. doi: 10.1038/s41598-017-14495-6.

3.

N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.

Ranieri R, Ciaglia E, Amodio G, Picardi P, Proto MC, Gazzerro P, Laezza C, Remondelli P, Bifulco M, Pisanti S.

Cell Death Differ. 2018 Feb;25(2):353-367. doi: 10.1038/cdd.2017.165. Epub 2017 Oct 13.

PMID:
29027991
4.

Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.

Proto MC, Fiore D, Piscopo C, Franceschelli S, Bizzarro V, Laezza C, Lauro G, Feoli A, Tosco A, Bifulco G, Sbardella G, Bifulco M, Gazzerro P.

Sci Rep. 2017 Sep 15;7(1):11678. doi: 10.1038/s41598-017-11688-x.

5.

Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.

Ciaglia E, Laezza C, Abate M, Pisanti S, Ranieri R, D'alessandro A, Picardi P, Gazzerro P, Bifulco M.

Int J Cancer. 2018 Jan 1;142(1):176-190. doi: 10.1002/ijc.31036. Epub 2017 Sep 21.

PMID:
28884474
6.

Immuno-Modulatory and Anti-Inflammatory Effects of Dihydrogracilin A, a Terpene Derived from the Marine Sponge Dendrilla membranosa.

Ciaglia E, Malfitano AM, Laezza C, Fontana A, Nuzzo G, Cutignano A, Abate M, Pelin M, Sosa S, Bifulco M, Gazzerro P.

Int J Mol Sci. 2017 Jul 28;18(8). pii: E1643. doi: 10.3390/ijms18081643.

7.

The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway.

Ciaglia E, Grimaldi M, Abate M, Scrima M, Rodriquez M, Laezza C, Ranieri R, Pisanti S, Ciuffreda P, Manera C, Gazzerro P, D'Ursi AM, Bifulco M.

Br J Pharmacol. 2017 Jul;174(14):2287-2301. doi: 10.1111/bph.13824. Epub 2017 Jun 11.

8.

Cannabidiol: State of the art and new challenges for therapeutic applications.

Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M.

Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Review.

PMID:
28232276
9.

Immunomodulatory properties of 1,2-dihydro-4-hydroxy-2-oxo-1,8-naphthyridine-3-carboxamide derivative VL15.

Malfitano AM, Laezza C, Bertini S, Marasco D, Tuccinardi T, Bifulco M, Manera C.

Biochimie. 2017 Apr;135:173-180. doi: 10.1016/j.biochi.2017.02.009. Epub 2017 Feb 20.

PMID:
28219703
10.

Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.

Ciaglia E, Abate M, Laezza C, Pisanti S, Vitale M, Seneca V, Torelli G, Franceschelli S, Catapano G, Gazzerro P, Bifulco M.

Int J Cancer. 2017 Feb 15;140(4):959-972. doi: 10.1002/ijc.30505. Epub 2016 Nov 16.

11.

PPARα Antagonist AA452 Triggers Metabolic Reprogramming and Increases Sensitivity to Radiation Therapy in Human Glioblastoma Primary Cells.

Benedetti E, d'Angelo M, Ammazzalorso A, Gravina GL, Laezza C, Antonosante A, Panella G, Cinque B, Cristiano L, Dhez AC, Astarita C, Galzio R, Cifone MG, Ippoliti R, Amoroso R, Di Cesare E, Giordano A, Cimini A.

J Cell Physiol. 2017 Jun;232(6):1458-1466. doi: 10.1002/jcp.25648. Epub 2016 Nov 30.

PMID:
27736000
12.

Endocannabinoid System in Neurological Disorders.

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):90-112. Review.

PMID:
27364363
13.

Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response.

Ranieri R, Laezza C, Bifulco M, Marasco D, Malfitano AM.

Recent Pat CNS Drug Discov. 2016;10(2):178-203. Review.

PMID:
27334610
14.

Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis.

Malfitano AM, Laezza C, Pisanti S, Manera C, Bifulco M.

Recent Pat CNS Drug Discov. 2016;10(2):113-121.

PMID:
27097974
15.

p53 regulates the mevalonate pathway in human glioblastoma multiforme.

Laezza C, D'Alessandro A, Di Croce L, Picardi P, Ciaglia E, Pisanti S, Malfitano AM, Comegna M, Faraonio R, Gazzerro P, Bifulco M.

Cell Death Dis. 2015 Oct 15;6:e1909. doi: 10.1038/cddis.2015.279.

16.

Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.

Fiore D, Proto MC, Pisanti S, Picardi P, Pagano Zottola AC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Williams DC, Campiani G, Gazzerro P, Bifulco M.

Cancer Biol Ther. 2016 Aug 2;17(8):849-58. doi: 10.1080/15384047.2015.1078028.

17.

Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells.

Ciaglia E, Torelli G, Pisanti S, Picardi P, D'Alessandro A, Laezza C, Malfitano AM, Fiore D, Pagano Zottola AC, Proto MC, Catapano G, Gazzerro P, Bifulco M.

Oncotarget. 2015 Jun 20;6(17):15464-81.

18.

New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.

Manera C, Malfitano AM, Parkkari T, Lucchesi V, Carpi S, Fogli S, Bertini S, Laezza C, Ligresti A, Saccomanni G, Savinainen JR, Ciaglia E, Pisanti S, Gazzerro P, Di Marzo V, Nieri P, Macchia M, Bifulco M.

Eur J Med Chem. 2015 Jun 5;97:10-8. doi: 10.1016/j.ejmech.2015.04.034. Epub 2015 Apr 24.

PMID:
25935384
19.

Anti Proliferative and Pro Apoptotic Effects of Flavonoid Quercetin Are Mediated by CB1 Receptor in Human Colon Cancer Cell Lines.

Refolo MG, D'Alessandro R, Malerba N, Laezza C, Bifulco M, Messa C, Caruso MG, Notarnicola M, Tutino V.

J Cell Physiol. 2015 Dec;230(12):2973-80. doi: 10.1002/jcp.25026.

PMID:
25893829
20.

Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration.

Pisanti S, Picardi P, Pallottini V, Martini C, Petrosino S, Proto MC, Vitale M, Laezza C, Gazzerro P, Di Marzo V, Bifulco M.

J Cell Physiol. 2015 Dec;230(12):2905-14. doi: 10.1002/jcp.24959.

PMID:
25684344
21.

N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Sosa S, Tubaro A, Vitale M, Gazzerro P, Malfitano AM, Bifulco M.

Pharmacol Res. 2014 Nov;89:1-10. doi: 10.1016/j.phrs.2014.07.003. Epub 2014 Jul 22.

PMID:
25063359
22.

Statins in neurological disorders: an overview and update.

Malfitano AM, Marasco G, Proto MC, Laezza C, Gazzerro P, Bifulco M.

Pharmacol Res. 2014 Oct;88:74-83. doi: 10.1016/j.phrs.2014.06.007. Epub 2014 Jun 19. Review.

PMID:
24954580
23.

1,2-Dihydro-2-oxopyridine-3-carboxamides: the C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor.

Lucchesi V, Parkkari T, Savinainen JR, Malfitano AM, Allarà M, Bertini S, Castelli F, Del Carlo S, Laezza C, Ligresti A, Saccomanni G, Bifulco M, Di Marzo V, Macchia M, Manera C.

Eur J Med Chem. 2014 Mar 3;74:524-32. doi: 10.1016/j.ejmech.2013.10.070. Epub 2014 Jan 21.

PMID:
24518874
24.

Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation.

Pisanti S, Picardi P, Ciaglia E, Margarucci L, Ronca R, Giacomini A, Malfitano AM, Casapullo A, Laezza C, Gazzerro P, Bifulco M.

FASEB J. 2014 Mar;28(3):1132-44. doi: 10.1096/fj.13-238238. Epub 2013 Nov 21.

PMID:
24265487
25.

N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.

Bifulco M, D'Alessandro A, Paladino S, Malfitano AM, Notarnicola M, Caruso MG, Laezza C.

FEBS J. 2013 Dec;280(23):6223-32. doi: 10.1111/febs.12544. Epub 2013 Nov 18.

26.

Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.

Malfitano AM, Laezza C, Saccomanni G, Tuccinardi T, Manera C, Martinelli A, Ciaglia E, Pisanti S, Vitale M, Gazzerro P, Bifulco M.

J Neuroimmune Pharmacol. 2013 Dec;8(5):1077-86. doi: 10.1007/s11481-013-9494-0. Epub 2013 Oct 1.

PMID:
24081326
27.

PBOX-15 induces apoptosis and improves the efficacy of oxaliplatin in human colorectal cancer cell lines.

Gangemi G, Gazzerro P, Fiore D, Proto MC, Butini S, Gemma S, Casagni A, Laezza C, Vitale M, Ligresti A, Di Marzo V, Zisterer DM, Nathwani S, Clive Williams D, Campiani G, Bifulco M.

Eur J Pharmacol. 2013 Aug 15;714(1-3):379-87. doi: 10.1016/j.ejphar.2013.07.011. Epub 2013 Jul 16. Retraction in: Eur J Pharmacol. 2014 Apr 5;728:190.

PMID:
23872382
28.

N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.

Ciaglia E, Pisanti S, Picardi P, Laezza C, Malfitano AM, D'Alessandro A, Gazzerro P, Vitale M, Carbone E, Bifulco M.

J Leukoc Biol. 2013 Dec;94(6):1207-19. doi: 10.1189/jlb.0413190. Epub 2013 Jul 11.

PMID:
23847096
29.

Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.

Malfitano AM, Laezza C, D'Alessandro A, Procaccini C, Saccomanni G, Tuccinardi T, Manera C, Macchia M, Matarese G, Gazzerro P, Bifulco M.

PLoS One. 2013 May 1;8(5):e62511. doi: 10.1371/journal.pone.0062511. Print 2013.

30.

The endocannabinoid signaling system in cancer.

Pisanti S, Picardi P, D'Alessandro A, Laezza C, Bifulco M.

Trends Pharmacol Sci. 2013 May;34(5):273-82. doi: 10.1016/j.tips.2013.03.003. Epub 2013 Apr 17. Review.

PMID:
23602129
31.

Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells.

Laezza C, d'Alessandro A, Malfitano AM, Bifulco M.

Eur J Cancer. 2013 May;49(8):2066-7. doi: 10.1016/j.ejca.2013.01.026. Epub 2013 Feb 21. No abstract available.

PMID:
23434151
32.

Cannabinoid type 1 receptor gene polymorphism and macronutrient intake.

Caruso MG, Gazzerro P, Notarnicola M, Cisternino AM, Guerra V, Misciagna G, Laezza C, Bifulco M.

J Nutrigenet Nutrigenomics. 2012;5(6):305-13. doi: 10.1159/000343563. Epub 2012 Nov 27.

33.

Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: an investigation of the 1,8-naphthyridin-2(1H)-one scaffold.

Manera C, Saccomanni G, Malfitano AM, Bertini S, Castelli F, Laezza C, Ligresti A, Lucchesi V, Tuccinardi T, Rizzolio F, Bifulco M, Di Marzo V, Giordano A, Macchia M, Martinelli A.

Eur J Med Chem. 2012 Jun;52:284-94. doi: 10.1016/j.ejmech.2012.03.031. Epub 2012 Mar 24.

PMID:
22483967
34.

Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA MB 231 cells.

Laezza C, D'Alessandro A, Paladino S, Maria Malfitano A, Chiara Proto M, Gazzerro P, Pisanti S, Santoro A, Ciaglia E, Bifulco M; Endocannabinoid Research Group.

Eur J Cancer. 2012 Nov;48(16):3112-22. doi: 10.1016/j.ejca.2012.02.062. Epub 2012 Mar 14.

PMID:
22425263
35.

The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.

Malfitano AM, Laezza C, Galgani M, Matarese G, D'Alessandro A, Gazzerro P, Bifulco M.

Pharmacol Res. 2012 Mar;65(3):365-71. doi: 10.1016/j.phrs.2011.11.008. Epub 2011 Nov 22.

PMID:
22123497
36.

Pharmacological actions of statins: a critical appraisal in the management of cancer.

Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M.

Pharmacol Rev. 2012 Jan;64(1):102-46. doi: 10.1124/pr.111.004994. Epub 2011 Nov 21. Review.

37.

Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis.

Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG, Morbidelli L, Gazzerro P, Ziche M, Das A, Bifulco M.

Blood. 2011 May 19;117(20):5541-50. doi: 10.1182/blood-2010-09-307355. Epub 2011 Apr 1.

38.

Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth.

Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, Laezza C, Bifulco M.

J Cell Physiol. 2012 Jan;227(1):250-8. doi: 10.1002/jcp.22727.

PMID:
21412772
39.

Update on the endocannabinoid system as an anticancer target.

Malfitano AM, Ciaglia E, Gangemi G, Gazzerro P, Laezza C, Bifulco M.

Expert Opin Ther Targets. 2011 Mar;15(3):297-308. doi: 10.1517/14728222.2011.553606. Epub 2011 Jan 19. Review.

PMID:
21244344
40.

Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice.

Malfitano AM, Sosa S, Laezza C, De Bortoli M, Tubaro A, Bifulco M.

Br J Pharmacol. 2011 Jan;162(1):84-93. doi: 10.1111/j.1476-5381.2010.01047.x.

41.

Effects of anandamide on polyamine levels and cell growth in human colon cancer cells.

Linsalata M, Notarnicola M, Tutino V, Bifulco M, Santoro A, Laezza C, Messa C, Orlando A, Caruso MG.

Anticancer Res. 2010 Jul;30(7):2583-9.

PMID:
20682986
42.

Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells.

Laezza C, Malfitano AM, Di Matola T, Ricchi P, Bifulco M.

Mol Carcinog. 2010 Oct;49(10):892-901. doi: 10.1002/mc.20666.

PMID:
20672320
43.

Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells.

Laezza C, Malfitano AM, Proto MC, Esposito I, Gazzerro P, Formisano P, Pisanti S, Santoro A, Caruso MG, Bifulco M.

Endocr Relat Cancer. 2010 May 18;17(2):495-503. doi: 10.1677/ERC-10-0009. Print 2010 Jun.

44.

Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm.

Aquila S, Guido C, Santoro A, Gazzerro P, Laezza C, Baffa MF, Andò S, Bifulco M.

Br J Pharmacol. 2010 Feb;159(4):831-41. doi: 10.1111/j.1476-5381.2009.00570.x. Epub 2010 Jan 8. Erratum in: Br J Pharmacol. 2017 Aug;174(16):2797.

45.

Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.

Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, Notarnicola M, Messa C, Laezza C, Misso G, Caraglia M, Bifulco M.

Oncol Rep. 2010 Jan;23(1):171-5.

PMID:
19956878
46.

Human sperm anatomy: ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction.

Aquila S, Guido C, Santoro A, Perrotta I, Laezza C, Bifulco M, Sebastiano A.

Anat Rec (Hoboken). 2010 Feb;293(2):298-309. doi: 10.1002/ar.21042.

47.

Cannabinoid receptor CB1 antagonists state of the art and challenges.

Bifulco M, Santoro A, Laezza C, Malfitano AM.

Vitam Horm. 2009;81:159-89. doi: 10.1016/S0083-6729(09)81007-8. Review.

PMID:
19647112
48.

A new role of anandamide in human sperm: focus on metabolism.

Aquila S, Guido C, Laezza C, Santoro A, Pezzi V, Panza S, Andò S, Bifulco M.

J Cell Physiol. 2009 Oct;221(1):147-53. doi: 10.1002/jcp.21837.

PMID:
19492411
49.

Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.

Santoro A, Pisanti S, Grimaldi C, Izzo AA, Borrelli F, Proto MC, Malfitano AM, Gazzerro P, Laezza C, Bifulco M.

Int J Cancer. 2009 Sep 1;125(5):996-1003. doi: 10.1002/ijc.24483.

50.

Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.

Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31. doi: 10.1016/j.beem.2009.02.001. Review.

PMID:
19285265

Supplemental Content

Loading ...
Support Center